JNJ-79635322
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 195 patients (estimated)
- Sponsors
- Janssen Research & Development LLC
- Tags
- B-Cell Maturation Antigen (BCMA), CD3, GPRC5D, Tri-specific Antibody
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1883
- NCT Identifier
- NCT05652335
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.